Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥ 19 years and \< 80 years~2. Diagnosis of mild-moderate AS or mild-moderate AR~3. Applicable to 2.0\~3.9 m/s of aortic jet velocity for mild-moderate AS or to 0.2\~0.6 cm of Vena contracta for mild-moderate AR~4. Diagnosis of hypertension (SBP \> 130 mmHg if being treated or SBP \> 140 mmHg if being untreated)~5. For females of childbearing potential; negative pregnancy test results during the screening period and prior to administration of the investigational product, and agreement on use of medically allowable contraceptive measures (condom, oral contraceptive pills, injectable or implantable contraceptives, intrauterine devices, birth control patches, etc.) during the study period~6. Voluntary written consent to taking part in the clinical study and willingness to comply with requirements of the study~Exclusion Criteria:~1. History of a cardiac valve replacement surgery (replacement surgery of mitral valve, aortic valve or tricuspid valve)~2. Accompanied by severe mitral regurgitation~3. Admitted to needing a surgery by the current treatment guidelines~4. Accompanied by symptoms such as angina pectoris, exertional dyspnea, syncope, etc.~5. \< 50% of left ventricular ejection fraction~6. History of hypersensitivity reaction to active ingredients of the investigational product (Amlodipine, Losartan and Chlorthalidone), dihydropyridine derivatives, thiazide drugs and other sulfonamide derivatives or their compositions~7. Pregnant or breastfeeding~8. Symptomatic orthostatic hypotension~9. Severe liver failure or renal failure (\< 30 mL/min of creatinine clearance)~10. Hereditary angioedema or history of angioedema at treatment with ACE inhibitors or angiotensin II receptor blockers~11. Primary hyperaldosteronism~12. Genetic problems such as galactose intolerance, Lapp Lapp lactase deficiency or glucose-galactose malabsorption~13. Anuria~14. Refractory hypokalemia~15. Hyponatremia or hypercalcemia~16. Symptomatic hyperuricemia (history of gout or uric acid lithiasis)~17. Untreated Addison's disease~18. Appropriately uncontrolled diabetes~19. Congenital or incurable hypertension~20. Diagnosis of severe cerebrovascular disorders (stroke, cerebral infarction, cerebral hemorrhage, etc.) within six months prior to the date of ICF obtainment~21. Wasting disease, autoimmune disease or connective tissue disease~22. Diagnosis of malignant tumor within five years prior to the date of ICF obtainment~23. Administration of another investigational product within four weeks prior to the date of ICF obtainment~24. For a patient who is taking anticoagulants and thrombolytic agents; considered difficult to keep a stable dosage/regimen by the investigator.~25. Considered unsuitable to be a subject by the investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- The intensive care group (Type: EXPERIMENTAL): The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -\> Losartan and Amlodipine 5/50 mg -\> Losartan and Amlodipine 5/100 mg -\> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition.
- The usual care group (Type: EXPERIMENTAL): The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -\> Losartan and Amlodipine 5/50 mg -\> Losartan and Amlodipine 5/100 mg -\> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).